Dr. Keqiang Zhang 张克强
Chief Physician
Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical, chemotherapy, radiotherapy, and targeted therapy for gynecologic malignancies, including refractory ovarian cancer, cervical cancer, and endometrial cancer. Expertise in minimally invasive surgery and management of recurrent or drug-resistant tumors.
Dr. Zhang holds an MD and serves as Professor and Director of the Fifth Gynecologic Oncology Department at Hunan Cancer Hospital. Dr. Zhang leads five provincial research projects and participates in National Natural Science Foundation studies. As Principal Investigator for multiple national multicenter clinical trials, Dr. Zhang has published over 30 academic papers.
Professional roles
- Chair, Family Hereditary Tumor Professional Committee, Hunan Anti-Cancer Association
- Chair, Cervical Cancer Prevention and Treatment Professional Committee, Hunan Female Physicians Association
- Vice Chair, Gynecology and Obstetrics Branch, Chinese Medical Association Hunan Branch
- Vice Chair, Gynecologic Oncology Branch, Hunan Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Keqiang). Papers usually list the name as Keqiang Zhang or Zhang K.
Selected publications
24 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Biochem Mol Toxicol, 2025 (senior author): ARL4C depletion suppresses the resistance of ovarian cancer to Carboplatin by disrupting cholesterol transport and autophagy via Notch-RBP-Jκ-H3K4Me3-OSBPL5. PubMed 41378627
- Commun Biol, 2024 (senior author): M2 macrophage-derived exosomal circTMCO3 acts through miR-515-5p and ITGA8 to enhance malignancy in ovarian cancer. PubMed 38755265
- Discov Oncol, 2024 (senior author): A cuproptosis-related signature predicts prognosis and indicates cross-talk with immunocyte in ovarian cancer. PubMed 38696071
- Chin Clin Oncol, 2023 (senior author): Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study. PubMed 37699603
- J Obstet Gynaecol Res, 2022 (senior author): LncRNA LAMTOR5-AS1 sponges miR-210-3p and regulates cervical cancer progression. PubMed 36173004
- Hum Exp Toxicol, 2022 (senior author): ARL4C depletion suppresses the resistance of ovarian cancer to carboplatin by disrupting cholesterol transport and autophagy via notch-RBP-Jκ-H3K4Me3-OSBPL5. PubMed 36366750
- Front Cell Dev Biol, 2021 (senior author): LncRNA RP11-499E18.1 Inhibits Proliferation, Migration, and Epithelial-Mesenchymal Transition Process of Ovarian Cancer Cells by Dissociating PAK2-SOX2 Interaction. PubMed 34621737
- Aging (Albany NY), 2020 (senior author): LINC00452 promotes ovarian carcinogenesis through increasing ROCK1 by sponging miR-501-3p and suppressing ubiquitin-mediated degradation. PubMed 33168781
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion